Analysts Predict ILCG Will Hit $112
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 18 2025
0mins
Should l Buy RVTY?
Source: NASDAQ.COM
ETF Performance Analysis: The iShares Morningstar Growth ETF (ILCG) has an implied analyst target price of $111.55, indicating a potential upside of 10.24% from its recent trading price of $101.19.
Notable Holdings with Upside: Key underlying holdings such as Revvity Inc (RVTY), Waters Corp. (WAT), and Fidelity National Information Services Inc (FIS) show significant upside potential, with RVTY at 27.30%, WAT at 24.24%, and FIS at 22.89% above their current prices.
Analyst Target Justification: There are questions regarding whether analysts' target prices are justified or overly optimistic, considering recent developments in the companies and industries involved.
Investor Research Importance: Investors are encouraged to conduct further research to determine the validity of analysts' targets and assess the risks associated with high price expectations relative to current trading prices.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RVTY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RVTY
Wall Street analysts forecast RVTY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RVTY is 113.38 USD with a low forecast of 105.00 USD and a high forecast of 123.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
6 Buy
4 Hold
0 Sell
Moderate Buy
Current: 99.520
Low
105.00
Averages
113.38
High
123.00
Current: 99.520
Low
105.00
Averages
113.38
High
123.00
About RVTY
Revvity, Inc. is a provider of health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. The Company has specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. Its segments include Life Sciences and Diagnostics. The Life Sciences segment provides products and services targeted towards the life sciences market. The segment offers instruments, reagents, software, detection and imaging technologies, and others. The Diagnostics segment develops diagnostics, tools, and applications focused on clinically oriented customers, within the reproductive health, immunodiagnostics, and applied genomics markets. The segment offers instruments, reagents, assay platforms and software to hospitals, medical labs, clinicians and medical research professionals to help improve the health of families.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Revvity Reports Strong Q4 Earnings, Beats Expectations
- Earnings Beat: Revvity reported Q4 2025 adjusted earnings of $1.70 per share, a 19.7% year-over-year increase, surpassing the consensus estimate of $1.55, indicating strong performance in the life sciences and diagnostics sector.
- Sales Growth: The company achieved sales of $772.06 million, up 6% year-over-year with 4% organic growth, exceeding the market expectation of $761.29 million, reflecting robust market demand.
- Positive Outlook: Revvity forecasts fiscal 2026 adjusted earnings between $5.35 and $5.45 per share, above the consensus of $5.32, demonstrating confidence in future growth prospects.
- Sales Guidance: The company anticipates fiscal 2026 sales between $2.96 billion and $2.99 billion, higher than the consensus of $2.93 billion, indicating a year-over-year growth of 4%-5% and organic growth of 2%-3%.
See More
Wall Street Analysts Adjust ROKU Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their outlook on ROKU stock, indicating a divergence in market sentiment regarding the company's future prospects, which could influence investor decisions and market mood.
- Market Reaction Monitoring: While specific rating changes were not detailed, analysts' opinions typically have a direct impact on stock prices, prompting investors to closely monitor subsequent market developments.
- Impact of Rating Changes: Upgrades or downgrades from analysts can lead to short-term volatility in ROKU's stock, making it essential for investors to consider these rating changes in their investment strategies.
- Investor Recommendations: When considering the purchase of ROKU stock, investors are advised to reference the latest analyst ratings and market trends to make more informed investment decisions.
See More
Revvity Q4 2025 Earnings Exceed Expectations
- Strong Financial Performance: Revvity reported $772 million in revenue for Q4 2025, reflecting a 4% year-over-year growth, with Diagnostics revenue reaching $390 million, up 10%, showcasing the company's resilience and growth potential in a challenging environment.
- Adjusted EPS Exceeds Expectations: The company achieved an adjusted EPS of $1.70, surpassing market expectations, with a full-year adjusted EPS of $5.06, indicating effective management strategies in response to adverse policy conditions.
- Robust Future Outlook: Management projects organic growth for 2026 to be in the range of 2% to 3%, with total expected revenue between $2.96 billion and $2.99 billion, reflecting a cautiously optimistic view on market recovery while emphasizing disciplined capital allocation.
- Strategic Investments and Innovations: Revvity announced the acquisition of ACD/Labs software and the launch of the AI models as a service platform Signals Xynthetica, which are expected to drive future revenue growth and enhance market competitiveness through collaboration with Lilly's TuneLab.
See More
Revvity Reports Q4 and FY 2025 Results, Shares Decline
- Earnings Report Reaction: Revvity's release of its Q4 and FY 2025 financial results led to a 5.07% drop in shares to $103.28, indicating market concerns over profitability and cost dynamics despite adjusted earnings growth.
- Strong Market Reaction: On the announcement day, Revvity's stock opened near $109, dipped to an intraday low of $102, and trading volume surpassed average levels, reflecting strong investor reactions to the earnings and guidance.
- Uneven Business Performance: While the company reported solid revenue and adjusted earnings, the market remained cautious due to uneven performance across business segments and margin pressure, contributing to a bearish sentiment.
- Cautious 2026 Outlook: Revvity's guidance for 2026 indicates continued growth but fails to fully alleviate market concerns regarding cost dynamics and profitability trends, leading to increased selling pressure.
See More
Revvity Reports Strong Q4 2025 Earnings, Exceeds Expectations
- Earnings Growth: Revvity reported adjusted earnings of $1.70 per share for Q4 2025, a 19.7% year-over-year increase that surpassed the consensus estimate of $1.55, indicating robust profitability and competitive strength.
- Sales Increase: The company achieved sales of $772.06 million, up 6% year-over-year with 4% organic growth, exceeding the market expectation of $761.29 million, reflecting sustained demand for its products in the market.
- Life Sciences Segment Performance: The Life Sciences segment generated $382 million in revenue, a 2% increase, although academic and government demand declined, the growth from pharma and biotech partially offset this, showcasing the segment's resilience.
- Future Guidance: Revvity forecasts adjusted earnings for fiscal 2026 to be between $5.35 and $5.45 per share, with sales projected at $2.96 billion to $2.99 billion, reflecting a year-over-year growth of 4%-5%, indicating the company's confidence and strategic planning for future market conditions.
See More
Revvity (RVTY) Q4 2025 Earnings Call Transcript
See More
Revvity Reports Strong Q4 Earnings, Beats Expectations
- Earnings Beat: Revvity reported Q4 2025 adjusted earnings of $1.70 per share, a 19.7% year-over-year increase, surpassing the consensus estimate of $1.55, indicating strong performance in the life sciences and diagnostics sector.
- Sales Growth: The company achieved sales of $772.06 million, up 6% year-over-year with 4% organic growth, exceeding the market expectation of $761.29 million, reflecting robust market demand.
- Positive Outlook: Revvity forecasts fiscal 2026 adjusted earnings between $5.35 and $5.45 per share, above the consensus of $5.32, demonstrating confidence in future growth prospects.
- Sales Guidance: The company anticipates fiscal 2026 sales between $2.96 billion and $2.99 billion, higher than the consensus of $2.93 billion, indicating a year-over-year growth of 4%-5% and organic growth of 2%-3%.
See More
Wall Street Analysts Adjust ROKU Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their outlook on ROKU stock, indicating a divergence in market sentiment regarding the company's future prospects, which could influence investor decisions and market mood.
- Market Reaction Monitoring: While specific rating changes were not detailed, analysts' opinions typically have a direct impact on stock prices, prompting investors to closely monitor subsequent market developments.
- Impact of Rating Changes: Upgrades or downgrades from analysts can lead to short-term volatility in ROKU's stock, making it essential for investors to consider these rating changes in their investment strategies.
- Investor Recommendations: When considering the purchase of ROKU stock, investors are advised to reference the latest analyst ratings and market trends to make more informed investment decisions.
See More
Revvity Q4 2025 Earnings Exceed Expectations
- Strong Financial Performance: Revvity reported $772 million in revenue for Q4 2025, reflecting a 4% year-over-year growth, with Diagnostics revenue reaching $390 million, up 10%, showcasing the company's resilience and growth potential in a challenging environment.
- Adjusted EPS Exceeds Expectations: The company achieved an adjusted EPS of $1.70, surpassing market expectations, with a full-year adjusted EPS of $5.06, indicating effective management strategies in response to adverse policy conditions.
- Robust Future Outlook: Management projects organic growth for 2026 to be in the range of 2% to 3%, with total expected revenue between $2.96 billion and $2.99 billion, reflecting a cautiously optimistic view on market recovery while emphasizing disciplined capital allocation.
- Strategic Investments and Innovations: Revvity announced the acquisition of ACD/Labs software and the launch of the AI models as a service platform Signals Xynthetica, which are expected to drive future revenue growth and enhance market competitiveness through collaboration with Lilly's TuneLab.
See More
Revvity Reports Q4 and FY 2025 Results, Shares Decline
- Earnings Report Reaction: Revvity's release of its Q4 and FY 2025 financial results led to a 5.07% drop in shares to $103.28, indicating market concerns over profitability and cost dynamics despite adjusted earnings growth.
- Strong Market Reaction: On the announcement day, Revvity's stock opened near $109, dipped to an intraday low of $102, and trading volume surpassed average levels, reflecting strong investor reactions to the earnings and guidance.
- Uneven Business Performance: While the company reported solid revenue and adjusted earnings, the market remained cautious due to uneven performance across business segments and margin pressure, contributing to a bearish sentiment.
- Cautious 2026 Outlook: Revvity's guidance for 2026 indicates continued growth but fails to fully alleviate market concerns regarding cost dynamics and profitability trends, leading to increased selling pressure.
See More
Revvity Reports Strong Q4 2025 Earnings, Exceeds Expectations
- Earnings Growth: Revvity reported adjusted earnings of $1.70 per share for Q4 2025, a 19.7% year-over-year increase that surpassed the consensus estimate of $1.55, indicating robust profitability and competitive strength.
- Sales Increase: The company achieved sales of $772.06 million, up 6% year-over-year with 4% organic growth, exceeding the market expectation of $761.29 million, reflecting sustained demand for its products in the market.
- Life Sciences Segment Performance: The Life Sciences segment generated $382 million in revenue, a 2% increase, although academic and government demand declined, the growth from pharma and biotech partially offset this, showcasing the segment's resilience.
- Future Guidance: Revvity forecasts adjusted earnings for fiscal 2026 to be between $5.35 and $5.45 per share, with sales projected at $2.96 billion to $2.99 billion, reflecting a year-over-year growth of 4%-5%, indicating the company's confidence and strategic planning for future market conditions.
See More
Revvity (RVTY) Q4 2025 Earnings Call Transcript
See More
